{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:45:25Z","timestamp":1792028725032,"version":"4.4.0"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"04","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The advent of disease-modifying therapies for neurodegenerative diseases may result in a growing demand for nuclear neuroimaging procedures presenting opportunities but also challenges to the nuclear medicine community. Whether capacity and expertise in Germany are sufficient to meet an increasing demand for nuclear neuroimaging is under discussion. Against this background, the Neuroimaging Working Group of the German Society of Nuclear Medicine initiated the first survey on the status of nuclear neuroimaging in Germany in 2023. 82 institutions participated in the survey: 33 practices, 15 community hospitals, 34 university hospitals. Primary findings were the following. In practices, brain scans are less frequently performed than in hospitals and are often limited to dopamine transporter SPECT. Brain PET is mainly performed in hospitals, and in community hospitals it is often restricted to FDG PET. Nevertheless, availability of amyloid PET with well-certified quality can be taken for granted. Thus, access to amyloid PET will not be a major bottleneck for new treatments of Alzheimer\u2019s disease. Adequate reimbursement and clear anchoring in clinical guidelines have the greatest potential to advance nuclear neuroimaging in Germany. Clinical dopamine transporter SPECT is largely in agreement with procedure guidelines. An area for improvement is the limited availability of MR images to avoid misinterpretation of structural\/vascular lesions as nigrostriatal degeneration. The survey provides the first systematic assessment of the status of nuclear neuroimaging in Germany. It underscores the capacity of the German nuclear medicine community to meet an increasing demand for neuroimaging procedures, its adherence to procedure guidelines and identifies topics for improvement.<\/jats:p>","DOI":"10.1055\/a-2566-1487","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T19:15:36Z","timestamp":1744744536000},"page":"250-261","source":"Crossref","is-referenced-by-count":5,"title":["The Status of Neuroimaging with SPECT and PET in Germany: Results from the 1st Survey on Nuclear Neuroimaging in Germany in 2023"],"prefix":"10.1055","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-0724","authenticated-orcid":false,"given":"Ralph","family":"Buchert","sequence":"first","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drzezga","sequence":"first","affiliation":[{"name":"Institute of Neuroscience and Medicine (INM-2), Forschungszentrum J\u00fclich, J\u00fclich, Germany"},{"name":"Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schreckenberger","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Johannes Gutenberg University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Josef","family":"Langen","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Medicine (INM-3\/INM-4\/INM-5\/INM-11), Forschungszentrum J\u00fclich, J\u00fclich, Germany"},{"name":"Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany"},{"name":"Center of Integrated Oncology, Aachen Bonn Cologne D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp T","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Medical Center \u2013 University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Working Group Nuclear Neuroimaging of the German Society of Nuclear Medicine (DGN e.V.)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-024-00630-2","article-title":"The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer\u02bcs disease","author":"M Sarazin","year":"2024","journal-title":"Nat Aging"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1038\/s41467-024-51502-7","article-title":"Acetyl-DL-leucine in two individuals with REM sleep behavior disorder improves symptoms, reverses loss of striatal dopamine-transporter binding and stabilizes pathological metabolic brain pattern-case reports","volume":"15","author":"WH Oertel","year":"2024","journal-title":"Nat Commun"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-021-05485-y","article-title":"The approval of a disease-modifying treatment for Alzheimer\u02bcs disease: impact and consequences for the nuclear medicine community","volume":"48","author":"V Garibotto","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00259-023-06177-5","article-title":"FDA approval of lecanemab: the real start of widespread amyloid PET use? \u2013 the EANM Neuroimaging Committee perspective","volume":"50","author":"A Verger","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07066-9","article-title":"Lecanemab approval in EU: what should we be ready for?- the EANM perspective","author":"I Yakushev","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1055\/a-2084-7454","article-title":"Myocardial Perfusion SPECT and ATTR imaging 2021 in Germany: Results of the 9th Survey","volume":"62","author":"O Lindner","year":"2023","journal-title":"Nuklearmed-Nucl Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13550-024-01149-8","article-title":"Brain perfusion SPECT in the presurgical evaluation of epilepsy: is additional ictal SPECT required in case of high-confidence lateralization of the seizure onset zone by interictal SPECT and vice versa?","volume":"14","author":"K Baradaran-Salimi","year":"2024","journal-title":"EJNMMI Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"NL Albert","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2024.1038","article-title":"Health Technology Review: Health System Readiness for Disease-Modifying Therapies for Alzheimer Disease","volume":"4","author":"Canada\u02bcs Drug Agency CDA-AMC","year":"2024","journal-title":"Canadian Journal of Health Technologies"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12383","article-title":"Patient-related benefits of amyloid PET imaging in dementia: Rationale and design of the German randomized coverage with evidence development study ENABLE","volume":"9","author":"SJ Teipel","year":"2023","journal-title":"Alzh Dement-Trci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"992","DOI":"10.2967\/jnumed.123.267291","article-title":"Is Permeability Surface Area Product of [(18)F]Florbetaben Comparable to That of H(2)O?","volume":"65","author":"M Kameyama","year":"2024","journal-title":"J Nucl Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13195-021-00785-9","article-title":"Data-driven FDG-PET subtypes of Alzheimer\u02bcs disease-related neurodegeneration","volume":"13","author":"F Levin","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cpet.2022.09.010","article-title":"Brain PET Imaging Frontotemporal Dementia","volume":"18","author":"J Ward","year":"2023","journal-title":"Pet Clin"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1212\/WNL.0b013e3181f11e35","article-title":"Distinct cerebral perfusion patterns in FTLD and AD","volume":"75","author":"WT Hu","year":"2010","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1750-3639.2008.00169.x","article-title":"Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: the Hisayama study","volume":"18","author":"K Fujimi","year":"2008","journal-title":"Brain Pathol"},{"issue":"S 1","key":"ref21","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1017\/cjn.2016.2","article-title":"The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic Review","volume":"43","author":"DB Hogan","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","article-title":"EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0","volume":"47","author":"S Morbelli","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/a-0807-8137","article-title":"Dopamine Transporter SPECT with I-123 labelled FP-CIT (DaTSCANTM)","volume":"58","author":"K Tatsch","year":"2019","journal-title":"Nuklearmedizin"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2967\/jnumed.123.266276","article-title":"Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole Collimators","volume":"65","author":"R Buchert","year":"2024","journal-title":"J Nucl Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1007\/s00259-023-06293-2","article-title":"No impact of attenuation and scatter correction on the interpretation of dopamine transporter SPECT in patients with clinically uncertain parkinsonian syndrome","volume":"50","author":"T Schiebler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Nuklearmedizin - NuclearMedicine"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2566-1487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T22:48:20Z","timestamp":1754520500000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2566-1487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":20,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2025,8,6]]},"published-print":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2566-1487","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]}}}